NEUREN PHARMACEUTICALS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.27 AUD | -6.33% |
|
-15.44% | -18.82% |
| May. 28 | Transcript : Neuren Pharmaceuticals Limited - Shareholder/Analyst Call | |
| May. 27 | Neuren Phase 2 Trial Shows Significant Improvements in Pitt Hopkins Syndrome | CI |
Evolution of the average Target Price on Neuren Pharmaceuticals Limited
Price target over the last 5 years
History of analyst recommendation changes
ef471494c7a995d8e174c2058e8.ej3cLUq6o3j-hcnovcoX4zcqsc0uVaFf9A8cxkcW5po.SAm1FQL05gK24OSy0LtvhnJ1ifpWMfgVlWkssnZbhO8NfoZvOvL2Kb3yug~c49e69e620e0e3d8733d42e87f26dddd
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
21.64
AUD
Average target price
28.56
AUD
Spread / Average Target
+31.97%
High Price Target
31
AUD
Spread / Highest target
+43.25%
Low Price Target
25
AUD
Spread / Lowest Target
+15.53%
Consensus detail
Consensus revision (last 18 months)
Trading Rating
Investor Rating
ESG Refinitiv
D+
EPS Revisions
- Stock Market
- Equities
- NEU Stock
- Consensus Neuren Pharmaceuticals Limited
